MDxHealth is trading $0.87 (+7.75%) after reporting Q2 revenue of $27.2 million, up 16% year over year.
- Extending the sharp August 14 rally while reaffirming 2026 revenue guidance of $110–115 million.
- Secured $20 million through a registered direct offering of 44,052,862 shares at $0.454 each, supporting liquidity but creating substantial dilution risk.
- Trading remains highly volatile after the prior session’s 74.89% gain.